{
    "clinical_study": {
        "@rank": "35070", 
        "brief_summary": {
            "textblock": "Assess efficacy and safety of topical MOB015B, applied daily during 48 weeks, in adults with\n      fungal nail infection."
        }, 
        "brief_title": "An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)", 
        "condition": "Distal Subungual Onychomycosis", 
        "condition_browse": {
            "mesh_term": "Onychomycosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female\n\n          2. 18 - 70 years\n\n          3. DSO of at least one of the great toe(s) affecting 25 % to 75 % of the target nail.\n\n          4. Positive culture for dermatophytes (i.e. Trichophyton species; T. rubrum or T.\n             mentagrophytes)\n\n          5. Signed written informed consent\n\n        Exclusion Criteria:\n\n          1. Proximal subungual onychomycosis.\n\n          2. DSO of both great toenails where involvement has extended into the proximal portion\n             of the target nail (unaffected proximal nail is less than 2 mm)\n\n          3. \"Spike\" of onychomycosis extending to eponychium of the target nail\n\n          4. Presence of dermatophytoma (defined as demarcated and localised thick masses of\n             fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target\n             nail\n\n          5. Other conditions than DSO known to cause abnormal nail appearance\n\n          6. Topical antifungal treatment of the nails within 1 month before screening\n\n          7. Systemic use of antifungal treatment within 3 months before screening\n\n          8. History or signs of peripheral circulatory insufficiency and/or diabetic neuropathy\n\n          9. Immunosuppression\n\n         10. Participation in another clinical trial with an investigational drug or device during\n             the previous 4 weeks before screening\n\n         11. Known allergy to any of the tested treatment products\n\n         12. A pregnancy test indicating pregnancy in a woman of childbearing potential at\n             screening (visit 1)\n\n         13. Pre-menopausal (last menstruation \u2264 1 year prior to screening) sexually active women\n             who :\n\n               -  are pregnant or nursing\n\n               -  are not surgically sterile\n\n               -  are of child bearing potential and not practising an acceptable method of birth\n                  control, or does not plan to continue practising an acceptable method of birth\n                  control throughout the trial (acceptable methods include intrauterine devices\n                  (IUD), oral, implantable or injectable contraceptives, diaphragm or cervical cap\n                  with intravaginal spermicide, condom with intravaginal spermicide or\n                  vasectomised partner)"
            }, 
            "gender": "Both", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814020", 
            "org_study_id": "MOB015B/Final 30-Aug-2012"
        }, 
        "intervention": {
            "intervention_name": "MOB015B", 
            "intervention_type": "Drug"
        }, 
        "keyword": "DSO", 
        "lastchanged_date": "June 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gothenburg", 
                    "country": "Sweden", 
                    "zip": "SE-413 45"
                }, 
                "name": "Hudkliniken Sahlgrenska Universitetssjukhuset"
            }
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of patients with mycological cure of the target nail,defined as negative fungal culture and negative direct microscopy at 60 weeks.", 
            "time_frame": "At 60 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814020"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Moberg Derma AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Moberg Derma AB", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}